Skip to content

    Platinum Industries Limited

    PLATIND
    Chemicals·13 Feb 2026
    Management Summary

    Platinum Industries delivered robust Q3 FY26 standalone revenue growth of 31% YoY, reaching ₹102.62 crores, fueled by strong demand in the PVC pipe segment. Despite a moderation in gross margins to 31% due to product mix shifts towards CPVC, the company maintains a net debt-free status and is actively pursuing strategic capacity expansions in Palghar and Egypt. Diversification into Pharma and Oleo Chemicals is also progressing, with management targeting significant revenue growth and margin expansion from these new ventures and geographies in the coming years.

    Highlights

    5
    • Q3 FY26 Standalone Revenue grew 31% YoY to ₹102.62 crores, driven by strong demand in PVC pipe and fittings.

    • 9M FY26 Standalone Revenue grew 25% YoY to ₹302.38 crores, reflecting strategic capacity expansions and deeper market penetration.

    • The company remains net debt-free, underscoring prudent financial management and a healthy cash position.

    • Strategic capacity expansions are progressing, with Palghar CPVC operational and Egypt plant expected to commence commercial production by September 2026.

    • New market entries into Pharma (Rivadu LifeSciences) and Oleo Chemicals derivatives are underway, diversifying future revenue streams.

    Concerns

    3
    • Gross margins moderated to ~31% (vs 32.6% in prior period) due to a higher proportion of lower-margin CPVC sales.

    • The Egypt plant commissioning has been delayed by 9-12 months, shifting associated revenue generation by one year.

    • 9M FY26 PAT moderation to ₹37.58 crores was impacted by higher depreciation from ongoing capacity expansion and lower other income.

    What Changed2

    vs Q4 FY26

    Guidance items11 → 13 (+2)Risks discussed2 → 3 (+1)

    Key financials

    Single quarter

    07 metrics
    1. 01Standalone Revenue₹102.62 Cr+31%YoY
    2. 02Consolidated Revenue₹104.67 Cr+12%YoY
    3. 03Gross Margins31%
    4. 04EBITDA₹16.25 Cr
    5. 05EBITDA Margin15.8%

    Capital allocation

    5
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt route, internal accruals, or equity raise for Oleo Chemicals Capex

    Debt

    Net ₹0 crores

    M&A

    Rivadu LifeSciences Pvt Ltd

    joint venture · announced

    M&A

    Platinum Oleo Chemicals

    Other · Other

    Liquidity

    Liquidity disclosed

    Company maintains a healthy cash position and liquidity for ongoing operation and future investment.

    Guidance & targets

    13
    CategoryTargetPriority
    Revenue
    Revenue Growth
    >40%
    High
    Revenue
    Revenue CAGR
    35%
    High
    Revenue
    Pharma Business Revenue
    Good revenue
    High
    Capacity
    Palghar Calcium Zinc Commercial Production
    Commercial production
    High
    Capacity
    Egypt Plant Commercial Production
    Commercial production
    Medium
    Revenue Potential
    Indian Factories Revenue Potential (PVC)
    ₹700-750 crores
    High
    Revenue Potential
    Indian Factories Revenue Potential (CPVC)
    ₹600 crores
    High
    Revenue Potential
    Egypt Plant Revenue Potential
    ₹250-300 crores
    High
    Capex
    Oleo Chemicals Capex
    ₹150-200 crores
    High
    Margin
    Egypt Lead Products Contribution Margin
    23-24%
    High
    Margin
    Egypt EBITDA Margin
    12-13%
    High
    Margin
    Egypt EBITDA Margin
    15-16%
    High
    Profitability
    Overall PAT Margin
    11-12%
    High

    Palghar Calcium Zinc Commercial Production

    next quarter
    CurrentAutomation problem corrected
    TargetCommercial production from April

    Why it matters

    Will contribute to domestic capacity utilization and product diversification, enhancing overall revenue potential.

    Regarding the calcium zinc, I think there was some problem with respect to the automation which has been corrected this month and probably from I think April, we should be having on a complete scale of production.

    How to verify

    guidance_and_targets

    Risks & concerns

    3
    RiskSeverity

    Margin Compression from Product Mix

    Gross margins moderated to ~31% due to a higher proportion of CPVC sales, which currently have lower margins compared to other products.Management acknowledged

    medium

    Delay in Egypt Plant Commissioning

    The Egypt plant commissioning has been delayed by 9-12 months, shifting the associated revenue generation by one year.Management acknowledged

    medium

    PVC Industry Degrowth

    The PVC industry experienced 10-12% degrowth from April to December 2025, though CPVC grew exponentially and PVC consumption started growing from January 2026.Management acknowledged

    low

    Q&A highlights

    7

    “So what I feel is in the month of January, from mid-January, the prices have reversed back due to the 13% rebate policy in China that was taken back by the government that has led to the prices going up and the sentiments of the farmers and the retailers have grown better. So what I see is from January, the orders that we have definitely helped us to understand that there is the future and the current run rate is growing for us. So the PVC consumption has grown from January this year.”

    Clarifies the recent positive shift in PVC market dynamics and its impact on volume growth, attributing it to external policy changes.

    asked by Bhargav Buddhadev

    2 min read5 chapters

    Detailed Narrative

    01

    Robust Revenue Growth Driven by PVC Segment

    Platinum Industries reported a strong Q3 FY26 standalone revenue of ₹102.62 crores, marking a robust 31% year-over-year growth. This expansion was primarily driven by the growing demand for products in the PVC pipe and fittings segment, benefiting from India's infrastructure boom. For the nine months ended December 31, 2025, the standalone top line reached ₹302.38 crores, up 25% from the previous year, indicating sustained growth momentum.

    02

    Margin Moderation and Product Mix Dynamics

    Gross margins for Q3 FY26 stood at approximately 31%, a moderation from 32.6% in the prior period. This was attributed to a higher proportion of CPVC sales, which currently have a lower margin compared to other products. Management noted that CPVC contribution margins have improved from 7% last year to ~17% in Q3 FY26, as the company works on raw material alternatives to enhance cost-effectiveness. Overall PAT for the nine-month period was ₹37.58 crores, impacted by higher depreciation from ongoing capacity expansion and lower other income.

    03

    Strategic Capacity Expansion and International Foray

    The company is actively pursuing significant capacity expansions. The CPVC phase at the Palghar facility is already operational, running at 60-65% of its 12,000 tonnes capacity, with commercial production for Calcium Zinc expected from April. The Egypt plant, a key international expansion, is projected to complete construction by May, begin pre-commissioning by June, and commence commercial production by September 2026, with a final outlook for 100% plant running by December 2026. This facility is expected to unlock high-growth international markets and add cost-efficient capacity.

    04

    Diversification into Pharma and Oleo Chemicals

    Platinum Industries is strategically diversifying its business. A new subsidiary, Rivadu LifeSciences Pvt Ltd (70% owned by Platinum), has been registered to enter the Pharma sector, focusing on nutraceuticals, APIs, excipients, and niche products, with revenue generation expected from FY27. Additionally, the company is investing in Platinum Oleo Chemicals, which develops derivatives for the polyolefin sector. A Capex of ₹150-200 crores is planned for next year to establish a 40,000-tonne capacity for Oleamides and derivatives, currently operating on a CDMO model.

    05

    Ambitious Growth Targets and Margin Outlook

    Management has set ambitious growth targets, aiming for over 40% revenue growth in FY27 and a 35% CAGR from FY26 to FY29. The revenue potential from Indian factories (PVC and CPVC) is estimated at ₹1,300-1,350 crores over 3-4 years, while the Egypt plant is targeted to generate ₹250-300 crores over three years. The Egypt facility is also expected to yield higher contribution margins for lead products (23-24% vs. 18-19% in India) and an initial EBITDA margin of 12-13%, projected to rise to 15-16%.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.